Lexeo Therapeutics, Inc. (LXEO) Stock Statistics & Valuation Metrics

Lexeo Therapeutics, Inc. has a market cap or net worth of $664.91M. The enterprise value is $290.61M.

Lexeo Therapeutics, Inc. has 72,987,330 shares outstanding. The number of shares has decreased by -2.65% in one year.

Lexeo Therapeutics, Inc.’s return on equity (ROE) is -0.84 and return on invested capital (ROIC) is -81.71%.

The current PE Ratio of Lexeo Therapeutics, Inc. is ―. Lexeo Therapeutics, Inc.’s PEG ratio is -0.09.

In the last 12 months, Lexeo Therapeutics, Inc. had revenue of 0.00 and earned -98.33M in profits. Earnings per share was -3.09.

In the last 12 months, operating cash flow was -106.81M and capital expenditures -384.00K, giving a free cash flow of -107.19M billion.

Lexeo Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Lexeo Therapeutics, Inc. upcoming earnings date is Mar 16, 2026, Before Open (Confirmed).

Lexeo Therapeutics, Inc. as a current ratio of 5.52, with Debt / Equity ratio of 6.45%

In the past 12 months, Lexeo Therapeutics, Inc. has paid 0.00 in taxes.

Lexeo Therapeutics, Inc. EV to EBITDA ratio is -1.91, with an EV/FCF ratio of -2.25.

Lexeo Therapeutics, Inc. has $41.00M in cash and marketable securities with $8.46M in debt, giving a net cash position of $32.54M billion.

Gross margin is -28.19%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Lexeo Therapeutics, Inc. is $20.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy